Merck & Co. and SurModics Inc. said on Wednesday they would seek to jointly develop drugs for eye diseases, a collaboration that could yield SurModics at least $300 million.

SurModics will receive a licensing fee of $20 million and could receive an additional $288 million associated with the successful product development and attainment of various U.S. and European regulatory approvals.